First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801
Chris Brearley, Sam Francis, John Reader, Judi Proctor · 2026
Read First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801 by Chris Brearley, Sam Francis, John Reader, Judi Proctor (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13619091.txt.
Description
Chris Brearley and three colleagues report a 2026 first-in-human trial of SDC-1801, an oral drug that blocks two signaling enzymes linked to autoimmune disease. Ninety-five healthy adults took part in a randomized phase I study. Early parts tested single and repeated doses against placebo, while a later part checked how food changed absorption of the drug.
No deaths or treatment-related serious events occurred, and no side effect was severe, with unrelated headache reported most often. Blood levels peaked a few hours after dosing and the drug stayed in the body long enough to support once- or twice-daily use. Markers of inflammation fell as exposure rose, which the authors read as evidence that the drug engaged both of its targets.
Catalog record
| CREATOR | Chris Brearley, Sam Francis, John Reader, Judi Proctor |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50470 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |